Matthew Davidson
Chief Development Officer and Director (CEO appointment pending stockholder vote September 17, 2026), ADIAL PHARMACEUTICALS, INC. · United States
Matthew Davidson is the CEO of ADIAL PHARMACEUTICALS, INC. (ADIL). Davidson is based in the United States.
Dr. Matthew Davidson is co-founder and former CEO of Azora Therapeutics. He joined Adial Pharmaceuticals in June 2026 as Chief Development Officer and Director following Adial's acquisition of Azora. He holds a degree from Stanford University School of Medicine.
Recent developments
AI summary of recent coverageRecent coverage has focused on Adial Pharmaceuticals undergoing significant executive and board transitions, with planned leadership changes tied to an upcoming annual meeting vote. The company has also secured $32 million in financing and granted stock to newly appointed executives as part of an expansion of its leadership team.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Matthew Davidson, it will appear here — and tie into the news timeline.
Matthew Davidson: FAQ
- Who is Matthew Davidson?
- Matthew Davidson is the Chief Development Officer and Director (CEO appointment pending stockholder vote September 17, 2026) of ADIAL PHARMACEUTICALS, INC., based in United States.
- What company does Matthew Davidson lead?
- Matthew Davidson is CEO of ADIAL PHARMACEUTICALS, INC..